ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 989

Reproductive Counseling Program For Lupus Patients At The Systemic Lupus Erythematosus-Antiphospholipid Syndrome Center Of Excellence At Hospital For Special Surgery

Katherine Kim1, Alana B. Levine2, Monica C. Richey2, Nadine H. Spring2, Elizabeth Schulman3, Lisa R. Sammaritano2, Shari E. Gelber4 and Jane E. Salmon2, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgey, New York, NY, 4Obstetrics, New York Presbyterian Hospital, New York, NY

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid syndrome and systemic lupus erythematosus (SLE), Counseling, Reproductive Health

  • Tweet
  • Email
  • Print
Session Information

Title: ARHP Education/Community Programs

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Maternal exposure to mycophenolate mofetil (MMF) during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Responding to this observation, the Food and Drug Administration (FDA) mandated a risk evaluation and mitigation strategy (REMS) for MMF in October 2012. MMF is currently used to treat a variety of conditions including systemic lupus erythematosus (SLE) and lupus nephritis.  The HSS SLE-APS Center of Excellence (COE) serves a large number of female patients of child-bearing potential. Based on these facts, we developed a survey to better understand the reproductive counseling needs of our cohort. The objectives were: a) To understand SLE patients’ pregnancy intentions and assess their current patterns of contraceptive use. b) To assess the level of contraceptive and reproductive counseling offered by the HSS SLE-APS COE and determine the need for and patient interest in contraceptive and reproductive patient education.

Methods: An anonymous, 9-question paper survey was offered to patients of the HSS SLE-APS COE from December 2010 to September 2011. Survey questions assessed attitudes about pregnancy, patterns and type of contraceptive use, prior pregnancy and contraceptive counseling by healthcare providers, and patients’ interest in participating in new reproductive health educational programs offered by the COE.

Results: Sixty-six patients completed the survey; 53 (80%) were female. 23 (35%) patients could recall a discussion with COE healthcare providers regarding contraceptive use; 22 (33%) remembered such a conversation about pregnancy.  56% were interested in participating in a contraception class and 53% were interested in a pregnancy class. (Table 1)

Conclusion: Our survey demonstrated a striking deficiency in recall of contraceptive and reproductive counseling by patients in our COE. Over half of survey participants were interested in a formal educational program on these topics. Based on data from this survey and the FDA’s mandate, the SLE-APS Center of excelence now offers a personalized, one-on-one, patient education session taught by a registered nurse for SLE patients taking MMF. Similar sessions for patients receiving cyclophosphamide, methotrexate, and azathioprine are being developed.

Table 1

Pregnancy Intentions (n=66)

            Pregnant                                               4 (6%)

Trying to become pregnant                    4 (6%)

            Wouldn’t mind becoming pregnant        13 (20%)

            Trying to avoid pregnancy                     29 (44%)

            Not possible to become pregnant          18 (27%)

            Haven’t considered pregnancy  2 (3%)

Contraceptive use (n=66)

            Never                                                   13 (20%)

            Rarely                                                  6 (9%)

            Sometimes                                            11 (17%)

            Most of the time                                   8 (12%)

            Always                                                 14 (21%)

            Not applicable                                      14 (21%)

Contraceptive type (n=34)

            None                                                    56 %

            Barrier                                                  35%

            Estrogen/progesterone pill                     3%

            Progesterone only pill                            3%

            Progesterone injection                           3%


Disclosure:

K. Kim,
None;

A. B. Levine,
None;

M. C. Richey,
None;

N. H. Spring,
None;

E. Schulman,
None;

L. R. Sammaritano,
None;

S. E. Gelber,
None;

J. E. Salmon,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reproductive-counseling-program-for-lupus-patients-at-the-systemic-lupus-erythematosus-antiphospholipid-syndrome-center-of-excellence-at-hospital-for-special-surgery/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology